胡南林, 李明舟, 朱安婕, 王佳玉, 罗扬, 马飞, 李青, 张频, 徐兵河, 袁芃. 热休克蛋白-90α在乳腺癌诊断和疗效监测及复发预测中的临床价值[J]. 中国肿瘤临床, 2018, 45(23): 1206-1209. DOI: 10.3969/j.issn.1000-8179.2018.23.771
引用本文: 胡南林, 李明舟, 朱安婕, 王佳玉, 罗扬, 马飞, 李青, 张频, 徐兵河, 袁芃. 热休克蛋白-90α在乳腺癌诊断和疗效监测及复发预测中的临床价值[J]. 中国肿瘤临床, 2018, 45(23): 1206-1209. DOI: 10.3969/j.issn.1000-8179.2018.23.771
shu
Hu Nanlin, Li Mingzhou, Zhu Anjie, Wang Jiayu, Luo Yang, Ma Fei, Li Qing, Zhang Pin, Xu Binghe, Yuan Peng. Clinical value of heat shock protein-90α on diagnosis, prediction of treatment response, and monitoring of relapse in breast cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 45(23): 1206-1209. DOI: 10.3969/j.issn.1000-8179.2018.23.771
Citation: Hu Nanlin, Li Mingzhou, Zhu Anjie, Wang Jiayu, Luo Yang, Ma Fei, Li Qing, Zhang Pin, Xu Binghe, Yuan Peng. Clinical value of heat shock protein-90α on diagnosis, prediction of treatment response, and monitoring of relapse in breast cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 45(23): 1206-1209. DOI: 10.3969/j.issn.1000-8179.2018.23.771
shu

热休克蛋白-90α在乳腺癌诊断和疗效监测及复发预测中的临床价值

Clinical value of heat shock protein-90α on diagnosis, prediction of treatment response, and monitoring of relapse in breast cancer

    摘要
  • 摘要:
      目的  探讨乳腺癌及其他恶性肿瘤患者血浆中的热休克蛋白-90α（heat shock protein-90α，HSP-90α）表达水平差异，及在乳腺癌诊断、监测疗效、预测复发中的临床价值。
      方法  选取2016年6月至2016年9月就诊于中国医学科学院肿瘤医院615例女性患者的临床病理资料，分为试验组399例和对照组216例。试验组均为乳腺癌患者，再分为静态组289例和动态组110例，静态组根据TNM分期、组织学类型和分子分型等进行分类分析，动态组用于动态疗效分析；对照组包括健康对照人群103例，乳腺良性肿瘤患者51例及非乳腺系统恶性肿瘤患者62例。采用酶联免疫法检测HSP-90α表达水平。利用ROC曲线分析确定血浆中HSP-90α表达水平作为乳腺癌诊断、复发的截断值，采用Wilcoxon符号秩检验及Kruskal-Wallis检验分析各因素与HSP-90α表达水平的相关性。
      结果  乳腺癌患者血浆中的HSP-90α表达水平显著升高（P < 0.001），且乳腺癌不同分子亚型患者血浆中的HSP-90α表达水平无显著性差异（P>0.05）。选取HSP-90α表达水平为59.7 ng/mL与43.22 ng/mL作为诊断乳腺癌和预测肿瘤复发的临界值时，其曲线下面积（area under curve，AUC）分别为0.834与0.877，灵敏度和特异度分别为90.3%和78.6%与95.7%和74.5%。新辅助治疗有效者及手术前后患者血浆中的HSP-90α表达水平明显下降（P < 0.05），
      结论  乳腺癌患者血浆中的HSP-90α表达水平显著升高，对乳腺癌诊断、疗效判断及复发预测具有一定的价值。

     

    Abstract:
      Objective  To explore the prognostic value of heat shock protein-90α (HSP-90α) plasma levels on breast cancer and nonbreast malignant tumors, monitoring the response of chemotherapy, and the predictive value of cancer recurrence and metastasis.
      Methods  A total of 615 female patients were enrolled between June 2016 and September 2016 in Cancer Hospital, Chinese Academy of Medical Sciences, who were divided into the examination (n=389) and control (n=216) groups. The former group consisted of static (n=289) and dynamic (n=110) groups, which were analyzed by stages, histological and molecular type, and so on. The latter group included healthy people (n=103), and those with breast benign tumors (n=51) and non-breast malignant tumors (n=62). In all the plasma samples, HSP-90α was detected using a double-antibody enzyme-linked immunosorbent assay. The receiving-operating characteristic curve was used to analyze the effectiveness of plasma HSP-90α in the diagnosis of breast cancer. Wilcoxon's rank test and the KruskalWallis test were used to analyze the association between clinical characteristics and levels of plasma HSP-90α.
      Results  The levels of plasma HSP-90α were significantly higher in patients with breast cancer than in healthy controls (P < 0.001). When the cut-off value was set as 59.7 ng/mL for the diagnosis of breast cancer and 43.22 ng/mL for disease recurrence, the areas under the curve were 0.834 and 0.877, sensitivities were 90.3% and 95.7%, and specificities were 78.6% and 74.5%, respectively. The levels of plasma HSP-90α significantly decreased after achieving a response to neoadjuvant chemotherapy or surgery (P < 0.05).
      Conclusions  Plasma HSP-90α has good clinical value in the diagnosis and monitoring of response and recurrence in breast cancer.

     

    • HTML全文
    • 参考文献(13)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回